It looks like you're using an outdated browser.

You can continue browsing with limited functionality or you may upgrade your browser here

Pioneering the future of personalized medicine.

About Biovest

At Biovest International, Inc., we believe in the power of the individual. We bring each patient’s immune system into the fight against cancer. Our vaccines are tailor-made to fight non-Hodgkin’s lymphoma, one patient at a time.

Leading the field of active personalized immunotherapy, we target life-threatening cancers of the blood system, market state-of-the-art bioreactors, and provide a full range of custom biomanufacturing services.

Carlos F. Santos, Ph.D.

Chief Executive Officer

Show Bio

On July 8, 2013, Dr. Carlos Santos was appointed as our Chief Executive Officer. Since 2009, Dr. Santos has managed all key aspects of our personalized immunotherapy platform, including our clinical and regulatory affairs, while also leading the development of our manufacturing systems essential to personalized cancer vaccine production. He designed and led the transition of the company’s vaccine manufacture into an automated process by developing software for automated systems integral to autologous vaccine manufacture. Dr. Santos has authored numerous peer-reviewed publications in the fields of active immunotherapy, oncology, and bioinformatics. He is a graduate of the University of Michigan, where he earned a Ph.D. in Bioinformatics, and Washington University (St. Louis), where he earned a B.S. in Computer Science. At the University of Michigan, Dr. Santos developed automated natural language processing systems to integrate high-throughput genomic experimental data with known protein interaction pathways in metastatic prostate cancer progression. He also led the development of a large-scale automated search and summarization engines for biomedical documents at the University of Michigan’s National Center for Integrative Biomedical Informatics. From 1998 to 2001, Dr. Santos was a researcher at Washington University’s Institute for Biomedical Computing (now the Center for Computational Biology).

Amy M. McCord, Ph.D.

Director of Chemistry, Manufacturing, and Controls

Show Bio

Dr. Amy McCord directs the manufacture and control of BiovaxID. Dr. McCord received her Ph.D. from the Department of Molecular Medicine at the University of South Florida College of Medicine in 2005. She subsequently devoted several years to cancer biology research as a postdoctoral fellow at the H. Lee Moffitt Cancer Center in the Drug Discovery program. Dr. McCord’s basic research background encompasses bacterial pathogenesis, angiogenesis, and DNA repair mechanisms of cancer stem cells. She authored several peer-reviewed manuscripts and abstracts presented at national meetings including the American Society of Clinical Oncology and the American Society of Hematology. Dr. McCord joined Biovest in 2009 to support the regulatory and scientific development of BiovaxID.

Daniel Chen, Ph.D.

Director of Bioinformatics and Automated Systems

Show Bio

Dr. Daniel Chen manages the initiative to expand Biovest’s capabilities in automated process R&D and cGMP manufacturing. As a bioinformatics expert with a decade of bench research experience, Daniel is well versed in both the technological and biomedical domains. Prior to joining Biovest in 2013, Daniel’s research focused on the development and application of ad hoc analytical pipelines to problems in developmental biology, cardiac hypertrophy, and obesity. Daniel received his Bachelor of Science in molecular Genetics from University of Toronto. He also holds a doctorate in Computational Biology from Washington University in St. Louis.

David J. States, M.D., Ph.D., FACMI

Chief Medical Officer

Show Bio

David J. States has been a member of the Biovest Scientific Advisory Board since 2011 and became Chief Medical Officer in March 2014. He is a leader in computational biology, genomics and proteomics. He received his MD and PhD from Harvard University and clinical training at the University of California, San Diego and the National Institutes of Health in Bethesda, Maryland. He is board certified in Internal Medicine and is a Fellow of the American College of Medical Informatics. His contributions include the widely used molecular dynamics program CHARMM, the development of advanced multidimensional NMR methods and BLASTX for genome analysis. He was involved in the inception of the Human Genome Project and helped to establish the NIH National Center for Biotechnology Information (NCBI). He served as Director of the Washington University Center for Genetics in Medicine, The Washington University Institute for Biomedical Computing and the University of Michigan Computational Biology Program. Dr. States was a founding member of the Board of Directors of the International Society for Computational Biology (ISCB) and established graduate training programs in Bioinformatics at Washington University in St. Louis and at the University of Michigan. Dr. States has served on scientific advisory boards for the St. Jude Hartwell Center, Protein Information Resource (PIR) and Gene Ontology (GO), and Wistar Institute and has been a member numerous NIH study sections and chair of the National Library of Medicine Biomedical Libraries and Information Resources Committee (BLIRC).

Recent News

Laying the Groundwork for Regulating and Developing Cancer Vaccines

Cancer immunotherapy has come a long way in the past few decades. When researchers began working on this technology, there were no FDA regulations in place to direct R&D.

Full Article

Double Down - Promise of Personalized Lymphoma Vaccine

It takes a great deal of patience, some faith and bit of madness to hold equity in pharmaceutical companies.

Full Article

Follicular Lymphoma Vaccine Specifically Targets Tumor Cells

There is ample research ongoing of immunotherapies and cancer vaccines, but the furthest along in the pipeline is a follicular lymphoma vaccine that is making its way to the FDA and other regulatory agencies in Europe and Canada.

Full Article

Made in Minnesota

Proudly manufacturing instruments and offering cell services since 1983.

Our facility in Minneapolis features automated systems that allow for global manufacturing of personalized vaccines. Here in Minnesota, we’ve pioneered personal-scale process automation in cell culture by developing automated micro-footprint AutovaxID bioreactor systems and disposable personal-scale protein purification instruments, along with deploying advanced liquid hardware and software to automate the cGMP process for personalized vaccines.

Contact Us

(763) 786-0302
1 (800) 325-1112


8500 Evergreen Blvd.
Minneapolis, MN 55433 USA


8500 Evergreen Blvd.
Minneapolis, MN 55433 USA


8500 Evergreen Blvd.
Minneapolis, MN 55433 USA